Cardiology (all articles)
ISCHEMIA Trial: Initial Invasive vs. Conservative Strategy for Stable Coronary Disease
31 Mar, 2020 | 04:28h | UTCCommentaries: International Study of Comparative Health Effectiveness With Medical and Invasive Approaches – ISCHEMIA – American College of Cardiology AND NIH-funded studies show stents and surgery no better than medication, lifestyle changes at reducing cardiac events – NIH News Releases
NICE Guideline: Venous Thromboembolic Diseases
30 Mar, 2020 | 02:27h | UTC
COVID-19 and Renin-Angiotensin System Blockers
30 Mar, 2020 | 02:00h | UTCRenin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers – Hypertension AND Commentary: COVID-19 alert: Heart and kidney patients should keep taking their medicines – University of Miami Miller School of Medicine
Related Guidelines: HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19 – American College of Cardiology AND The Renal Association, UK position statement on COVID-19 and ACE Inhibitor/Angiotensin Receptor Blocker use AND Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers – European Society of Cardiology
Review: Potential Effects of Coronaviruses on the Cardiovascular System
30 Mar, 2020 | 01:41h | UTCPotential Effects of Coronaviruses on the Cardiovascular System: A Review – JAMA Cardiology
Editorial: Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality
Related Articles: Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China – JAMA Cardiology AND Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) – JAMA Cardiology
Commentary: A Heart Attack? No, It Was the Coronavirus – The New York Times
#ACC20 – [Abstract only] Randomized Trial: Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery
30 Mar, 2020 | 01:20h | UTCRivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: PRONOMOS: Rivaroxaban Better Than Enoxaparin in Preventing VTE After Nonmajor Orthopedic Surgery – American College of Cardiology (free) AND PROphylaxis in NON-Major Orthopedic Surgery – PRONOMOS – American College of Cardiology (free)
Just Presented at the 2020 American College of Cardiology Virtual Meeting (free access)
#ACC20 – [Abstract Only] Randomized Trial: Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation
30 Mar, 2020 | 01:13h | UTCAnticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: Antithrombotic Therapy After Transcatheter Aortic Valve Implantation in Patients With a Long-Term Indication for Oral Anticoagulation – POPular TAVI – American College of Cardiology (free)AND A-fib Patients Undergoing TAVR Do Better With OAC Alone: POPular TAVI – TCTMD (free)
Just Presented at the 2020 American College of Cardiology Virtual Meeting (free access)
#ACC20 – [Abstract Only] Randomized Trial: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
30 Mar, 2020 | 01:18h | UTCVericiguat in Patients with Heart Failure and Reduced Ejection Fraction – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA – TCTMD (free) AND VICTORIA: Vericiguat Associated With Reduced CV Death, HF Hospitalization in High-Risk HF Patients – American College of Cardiology
Just Presented at the 2020 American College of Cardiology Virtual Meeting (free access)
#ACC20 – [Abstract Only] Randomized Trial: Rivaroxaban in Peripheral Artery Disease after Revascularization
30 Mar, 2020 | 01:05h | UTCRivaroxaban in Peripheral Artery Disease after Revascularization – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: VOYAGER-PAD: Rivaroxaban Associated With Reduced Adverse Limb, CV Events in PAD Patients – American College of Cardiology (free) AND VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events – TCTMD (free)
Just Presented at the 2020 American College of Cardiology Virtual Meeting (free access)
#ACC20 – Randomized Trial: Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
30 Mar, 2020 | 01:03h | UTCSee also: Visual Abstract
Just Presented at the 2020 American College of Cardiology Virtual Meeting (free access)
#ACC20 – [Abstract Only] Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
30 Mar, 2020 | 01:12h | UTCApixaban for the Treatment of Venous Thromboembolism Associated with Cancer – New England Journal of Medicine (abstract Only – $ for full-text)
Commentaries: Caravaggio Trial: Apixaban Noninferior to Dalteparin in Treatment of Cancer-Associated VTE – American College of Cardiology (free) AND Apixaban, Dalteprin Shown to Have Same Bleeding Risk in Patients With Cancer – AJMC (free)
Just Presented at the 2020 American College of Cardiology Virtual Meeting (free access)
Typical and Atypical Symptoms of Acute Coronary Syndrome: Time to Retire the Terms?
27 Mar, 2020 | 03:44h | UTC
Study: Association of Daily Step Count and Step Intensity with Mortality
27 Mar, 2020 | 03:38h | UTCAssociation of Daily Step Count and Step Intensity with Mortality Among US Adults – JAMA (free for a limited period)
Commentaries: Higher daily step count linked with lower all-cause mortality – NIH News Releases (free) AND The number of steps per day, not speed, is linked to mortality rate – Science News AND Association of Daily Step Count and Step Intensity With Mortality – American College of Cardiology (free)
Cohort Study: Multicenter Emergency Department Validation of the Canadian Syncope Risk Score
27 Mar, 2020 | 03:21h | UTCMulticenter Emergency Department Validation of the Canadian Syncope Risk Score – JAMA Internal Medicine (free for a limited period)
Commentary: Emergency Department Validation of Canadian Syncope Risk Score – American College of Cardiology
Randomized Trial: Aspirin Not Beneficial for Reducing the Risk of Dementia, MCI, or Cognitive Decline
26 Mar, 2020 | 02:20h | UTCCommentary: Study: An aspirin a day does not keep dementia at bay – American Academy of Neurology (free)
Studies: Cardiac Injury Associated with Increased Mortality in Hospitalized Patients With COVID-19
26 Mar, 2020 | 02:21h | UTC- Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China – JAMA Cardiology AND Commentaries: Cardiac injury linked to increased mortality in COVID-19 – MedicalXpress AND Cardiac injury in COVID-19 patients associated with higher in-hospital mortality – Cardiovascular Business AND Cardiac Injury and Mortality in Hospitalized COVID-19 Patients – American College of Cardiology
- Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis – Progress in Cardiovascular Diseases AND Commentary: Meta-Analysis on Troponin I in Patients With Coronavirus – Latest in Cardiology
Review: Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease
25 Mar, 2020 | 02:43h | UTCCoronavirus Disease 2019 (COVID-19) and Cardiovascular Disease – Circulation
See also: COVID-19: Updates for Cardiologists
AHA: Interim Guidance to Reduce COVID-19 Transmission During Resuscitation Care
25 Mar, 2020 | 02:47h | UTCInterim Guidance for Healthcare Providers during COVID-19 Outbreak – American Heart Association (free PDF)
News Release: Interim guidance to reduce COVID-19 transmission during resuscitation care – American Heart Association (free)
See also: COVID-19: Updates for Cardiologists
COVID-19: Updates for Cardiologists
25 May, 2020 | 00:01h | UTCPodcasts:
- Practice Made Perfect: What You Need to Know Now About Managing Individuals With COVID-19 – American College of Cardiology (04/2020)
- Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality – JAMA Cardiology (03/2020)
Guidelines:
- Current perspectives on Coronavirus 2019 (COVID‐19) and cardiovascular disease: A white paper by the JAHA editors – Journal of the American Heart Association
- Safe Reintroduction of Cardiovascular Services during the COVID-19 Pandemic: Guidance from North American Societies
- EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic – European Heart Journal (05/2020)
- COVID-19 rapid guideline: acute myocardial injury – National Institute for Health and Care Excellence (04/2020)
- ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic – European Society of Cardiology (04/2020)
- Interim Guidance for Basic and Advanced Life Support in Adults, Children, and Neonates With Suspected or Confirmed COVID-19: From the Emergency Cardiovascular Care Committee and Get With the Guidelines®-Resuscitation Adult and Pediatric Task Forces of the American Heart Association in Collaboration with the American Academy of Pediatrics, American Association for Respiratory Care, American College of Emergency Physicians, The Society of Critical Care Anesthesiologists, and American Society of Anesthesiologists: Supporting Organizations: American Association of Critical Care Nurses and National EMS Physicians – Circulation AND News Release: Interim CPR guidelines address challenges of providing resuscitation during COVID-19 pandemic – American Heart Association (04/2020)
- Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment – Circulation AND News Release: Caution recommended on COVID-19 treatment with hydroxychloroquine and azithromycin for patients with cardiovascular disease – American Heart Association AND Commentaries: Medical groups urge caution when using hydroxychloroquine, azithromycin to treat COVID-19 patients with CVD – Cardiovascular Business AND AHA, ACC, HRS Caution Use of COVID-19 Therapies Hydroxychloroquine and Azithromycin in Cardiac Patients – DAIC (04/2020)
- Triage Considerations for Patients Referred for Structural Heart Disease Intervention During the Coronavirus Disease 2019 (COVID-19) Pandemic: An ACC /SCAI Consensus Statement – JACC: Cardiovascular Interventions AND Commentary: ACC/SCAI Consensus Document Guides Triage For Structural Heart Disease During COVID-19 Pandemic (04/2020)
- COVID-19 pandemic and cardiac imaging: EACVI recommendations on precautions, indications, prioritization, and protection for patients and healthcare personnel – European Heart Journal – Cardiovascular Imaging (04/2020)
- Guidance for Cardiac Electrophysiology During the Coronavirus (COVID-19) Pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology, American Heart Association – Heart Rhythm (04/2020)
- CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic – Circulation (03/2020)
- Recommendations from the Peking Union Medical College Hospital for the management of acute myocardial infarction during the COVID-19 outbreak – European Heart Journal (04/2020)
- Resuscitation Council UK Statements on COVID-19 (Coronavirus), CPR and Resuscitation (03/2020)
- Society of Cardiovascular Computed Tomography Guidance for Use of Cardiac Computed Tomography Amidst the COVID-19 Pandemic – Journal of Cardiovascular Computed Tomography AND Commentary: ACC Endorses Clinical Guidance on Cardiovascular CT – American College of Cardiology (03/2020)
- General Guidance on Deferring Non-Urgent CV Testing and Procedures During the COVID-19 Pandemic – American College of Cardiology (03/2020)
- Interim Guidance for Healthcare Providers during COVID-19 Outbreak – American Heart Association AND News Release: Interim guidance to reduce COVID-19 transmission during resuscitation care – American Heart Association (03/2020)
- Troponin and BNP Use in COVID-19 – Cardiology Magazine, American College of Cardiology (03/2020)
- Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic – Journal of the American College of Cardiology AND Commentary: CVD in the Setting of COVID-19: Considerations to Prepare Patients, Providers, Health Systems – American College of Cardiology (03/2020)
- HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19 – American College of Cardiology AND Commentaries: Patients with COVID-19 should keep taking key CVD medications – Cardiovascular Business AND Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician – American Heart Association (03/2020)
- The Renal Association, UK position statement on COVID-19 and ACE Inhibitor/Angiotensin Receptor Blocker use (03/2020)
- Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers – European Society of Cardiology (03/2020)
Selected Articles:
- NEW – Reductions in Heart Failure Hospitalizations During the COVID-19 Pandemic – Journal of Cardiac Failure (05/2020)
- NEW – Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy – European Heart Journal AND Commentary: Outcomes of Patients Hospitalized for COVID-19 and Cardiac Disease – American College of Cardiology (05/2020)
- NEW – Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19) – Journal of Cardiovascular Pharmacology (05/2020)
- NEW – The Covid-19 Pandemic and the Incidence of Acute Myocardial Infarction – New England Journal of Medicine (05/2020)
- NEW – ACEI/ARB Use and Risk of Infection or Severity or Mortality of COVID-19: A Systematic Review and Meta-analysis – Pharmacological Research (05/2020)
- Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit – JAMA Cardiology
- Editorial: Inhibitors of the Renin–Angiotensin–Aldosterone System and Covid-19 – New England Journal of Medicine
- Study 1: Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19 – New England Journal of Medicine
- Study 2: Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19 – New England Journal of Medicine
- Study 3: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 – New England Journal of Medicine
- Study 4: Effects Of ARBs And ACEIs On Virus Infection, Inflammatory Status And Clinical Outcomes In COVID-19 Patients With Hypertension: A Single Center Retrospective Study – Hypertension
- Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era – Diabetes Care (05/2020)
- QT Interval Prolongation and Torsade De Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin – Heart Rhythm (05/2020)
- Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019 – European Heart Journal (05/2020)
- Recognizing COVID-19-related myocarditis: the possible pathophysiology and proposed guideline for diagnosis and management – Heart Rhythm (05/2020)
- Challenges For the Cardiovascular Community During the COVID-19 Pandemic – ACC Cardiology Magazine (05/2020)
- Surfing the Waves of the COVID-19 Pandemic As A Cardiovascular Clinician – Circulation (05/2020)
- Multivessel coronary thrombosis in a patient with COVID-19 pneumonia – European Heart Journal (05/2020)
- [Preprint] Impact of hospitalised patients with COVID-19 taking Renin-Angiotensin-Aldosterone System inhibitors: a systematic review and meta-analysis – medRxiv (05/2020)
- Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty – Current Cardiology Reports (05/2020)
- Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19) – JAMA Cardiology (05/2020)
- Cardiac considerations in patients with COVID-19 – Canadian Medical Association Journal (05/2020)
- Cardiovascular manifestations and treatment considerations in covid-19 – Heart (05/2020)
- COVID-19 and the Cardiovascular System: Implications for Risk Assessment, Diagnosis, and Treatment Options – Cardiovascular Research (05/2020)
- Hypertension is a clinically important risk factor for severe illness and mortality in COVID‐19 – Anaesthesia (05/2020)
- Understanding the Renin-Angiotensin Aldosterone-SARS-CoV-Axis: A Comprehensive Review – European Respiratory Review (05/2020)
- Reduced Rate of Hospital Admissions for ACS during Covid-19 Outbreak in Northern Italy – New England Journal of Medicine (05/2020)
- Renin–angiotensin–aldosterone system inhibitors and COVID-19 – Canadian Medical Association Journal (05/2020)
- Cardiac injury is associated with mortality and critically ill pneumonia in COVID-19: A meta-analysis – American Journal of Emergency Medicine (05/2020)
- Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes – The Lancet (04/2020)
- Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China – JAMA Cardiology AND Commentary: Drugs for high blood pressure don’t appear to make COVID-19 worse – Science News (04/2020)
- Cardiovascular complications in COVID-19 – American Journal of Emergency Medicine (04/2020)
- Clare Taylor: For people with heart failure, covid-19 presents a challenge – The BMJ Opinion (04/2020)
- Cardio-oncology Care in the Time of COVID-19 and the Role of Telehealth – JACC: CardioOncology (04/2020)
- Elevated troponin in patients with Coronavirus Disease 2019 (COVID-19): possible mechanisms – Journal of Cardiac Failure (04/2020)
- The Obstacle Course of Reperfusion for STEMI in the COVID-19 Pandemics – Circulation (04/2020)
- Primary and Secondary Prevention of Cardiovascular Disease in the Era of the Coronavirus Pandemic – Circulation (04/2020)
- Antimalarials widely used against COVID-19 heighten risk of cardiac arrest. How can doctors minimize the danger? – Science (04/2020)
- Management of Acute Myocardial Infarction During the COVID-19 Pandemic – Journal of the American Academy of Cardiology (04/2020)
- Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome – Circulation (04/2020)
- ST-Segment Elevation in Patients with Covid-19 — A Case Series – New England Journal of Medicine (04/2020)
- The Science Underlying COVID-19: Implications for the Cardiovascular System – Circulation (04/2020)
- COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up – Journal of the American College of Cardiology AND Commentary: JACC Paper Outlines Implications, Considerations For Thrombotic Disease Patients During COVID-19 Pandemic – American College of Cardiology (04/2020)
- Priorities for Cath labs in the COVID-19 tsunami: Roberto Ferrari and co-authors present a procedure to follow subsequent to the outbreak in Italy – European Heart Journal AND Commentaries: Priorities for Cath Labs in the COVID-19 Tsunami – American College of Cardiology (04/2020)
- Related: Reperfusion of STEMI in the COVID-19 Era – Business as Usual? – Circulation AND As COVID-19 Spreads, US Cath Labs Ponder Fibrinolytics for STEMI – TCTMD (04/2020)
- Disruptive Modifications to Cardiac Critical Care Delivery During the Covid-19 Pandemic: An International Perspective – Journal of the American College of Cardiology (04/2020)
- Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 – Circulation Research (04/2020)
- COVID-19 and Renin Angiotensin Blockers: Current Evidence and Recommendations – Circulation AND Commentary: COVID-19 and Renin Angiotensin Blockers – American (04/2020)
- Antiplatelet Therapy Following Percutaneous Coronary Intervention in Patients Complicated by COVID-19: Implications from Clinical Features to Pathological Findings – Circulation (04/2020)
- The double burden of disease of COVID-19 in cardiovascular patients: overlapping conditions could lead to overlapping treatments – European Journal of Epidemiology (04/2020)
- Management of the Hospitalized COVID-19 Patient With Acute Cardiomyopathy or Heart Failure – American College of Cardiology (04/2020)
- The Novel Coronavirus Disease (COVID-19) Threat for Patients with Cardiovascular Disease and Cancer – JACC CardioOncology (04/2020)
- Covid-19 and hypertension: risks and management – The BMJ Opinion (04/2020)
- End-stage Heart Failure with COVID-19: Strong Evidence of Myocardial Injury by 2019-nCoV – JACC: Heart Failure (04/2020)
- Reduction in ST-Segment Elevation Cardiac Catheterization Laboratory Activations in the United States during COVID-19 Pandemic – Journal of the American College of Cardiology (04/2020)
- COVID-19-related myocarditis in a 21-year-old female patient – European Heart Journal (04/2020)
- Cardiovascular Considerations in Treating Patients with Coronavirus (COVID-19) – Journal of Cardiovascular Pharmacology (04/2020)
- COVID-19, Arrhythmic Risk and Inflammation: Mind the Gap! – Circulation (04/2020)
- Perspective: cardiovascular disease and the Covid-19 pandemic – Basic Research in Cardiology (04/2020)
- Reperfusion of STEMI in the COVID-19 Era – Business as Usual? – Circulation (04/2020)
- First case of COVID-19 complicated with fulminant myocarditis: a case report and insights – Infection (04/2020)
- Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society – Indian Pacing and Electrophysiology Journal (04/2020)
- Editorial: Cardiopulmonary Resuscitation after Hospital Admission with Covid-19 – The BMJ (04/2020)
“This pandemic has changed the risk-benefit balance for CPR: from “there is no harm in trying” to “there is little benefit to the patient, and potentially significant harm to staff.””
- Clinical Characteristics of Patients Who Died of Coronavirus Disease 2019 in China – JAMA Network Open AND Commentary: New Wuhan Data Confirm High Hypertension Rate in COVID-19 Deaths – TCTMD (04/2020)
- In-hospital cardiac arrest outcomes among patients with COVID-19 pneumonia in Wuhan, China – Resuscitation (04/2020)
- Recommendations on cardiopulmonary resuscitation strategy and procedure for novel coronavirus pneumonia – Resuscitation (04/2020)
- COVID-19 and the Heart – Circulation Research (04/2020)
- The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease – International Journal of Cardiology (04/2020)
- Myocardial localization of coronavirus in COVID‐19 cardiogenic shock – European Journal of Heart Failure (04/2020)
- Palliative Care Considerations For Patients With Cardiovascular Disease Under COVID-19 – American College of Cardiology (04/2020)
- Cardiac and arrhythmic complications in Covid‐19 patients – Journal of Cardiovascular Electrophysiology (04/2020)
- [Preprint] Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study – medRxiv (04/2020)
- [Preprint] Treatment with ACE-inhibitors is associated with less severe disease with SARS-Covid-19 infection in a multi-site UK acute Hospital Trust – medRxiv (04/2020)
- ST-segment Elevation, Myocardial Injury, and Suspected or Confirmed COVID-19 Patients: Diagnostic and Treatment Uncertainties – Mayo Clinic Proceedings AND News Release: Mayo Clinic experts offer guidance on treating COVID-19 patients with signs of acute heart attack – Mayo Clinic (04/2020)
- Complete Guide to CARDIAC Ultrasound in COVID-19 (Coronavirus) – POCUS 101 (04/2020)
- Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019 – Mayo Clinic Proceedings (04/2020)
- Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19 – Mayo Clinic Proceedings (04/2020)
- Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection – European Heart Journal (04/2020)
- Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019 – Mayo Clinic Proceedings (04/2020)
- Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients – eLife (04/2020)
- Cardiovascular disease and COVID-19 – Diabetes & Metabolic Syndrome: Clinical Research & Reviews (04/2020)
- Coronavirus Disease 2019 (COVID-19): Epidemiology, Clinical Spectrum and Implications for the Cardiovascular Clinician – American College of Cardiology (04/2020)
- Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers – JAMA Cardiology (04/2020)
- The Dilemma of Coronavirus Disease 2019, Aging, and Cardiovascular Disease: Insights From Cardiovascular Aging Science – JAMA Cardiology (04/2020)
- Controversies of renin–angiotensin system inhibition during the COVID-19 pandemic – Nature Reviews Nephrology (04/2020)
- The Variety of Cardiovascular Presentations of COVID-19 – Circulation (04/2020)
- Angiotensin-Converting Enzyme 2 and Anti-Hypertensives (Angiotensin Receptor Blockers and Angiotensin Converting Enzyme Inhibitors) in Coronavirus Disease 2019 (COVID-19) – Mayo Clinic Proceedings AND Commentary: Blood Pressure Meds ACEIS and ARBS and Covid-19 Infection – MedicalResearch.com (04/2020)
- Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19 – American College of Cardiology (03/2020)
- Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19 – New England Journal of Medicine (03/2020)
- Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China – JAMA Cardiology AND Commentaries: Cardiac injury linked to increased mortality in COVID-19 – MedicalXpress AND Cardiac injury in COVID-19 patients associated with higher in-hospital mortality – Cardiovascular Business AND Cardiac Injury and Mortality in Hospitalized COVID-19 Patients – American College of Cardiology (03/2020)
- Viewpoint: An Acute Respiratory Infection Runs Into the Most Common Noncommunicable Epidemic—COVID-19 and Cardiovascular Diseases – JAMA Cardiology (03/2020)
- COVID-19 Illness and Heart Failure: A Missing Link? – JACC: Heart Failure (03/2020)
- COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence? – JAMA (03/2020)
- Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis – Progress in Cardiovascular Diseases AND Commentary: Meta-Analysis on Troponin I in Patients With Coronavirus – Latest in Cardiology (03/2020)
- Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on ST-Segment–Elevation Myocardial Infarction Care in Hong Kong, China – Circulation: Cardiovascular Quality and Outcomes (03/2020)
- Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin – European Heart Journal (03/2020)
- How to balance acute myocardial infarction and COVID-19: the protocols from Sichuan Provincial People’s Hospital – Intensive Care Medicine (03/2020)
- Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? – The Lancet Respiratory Medicine (03/2020)
- Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China – Clinical Research in Cardiology (03/2020)
- How to balance acute myocardial infarction and COVID-19: the protocols from Sichuan Provincial People’s Hospital – Intensive Care Medicine (free)
- Potential Effects of Coronaviruses on the Cardiovascular System: A Review – JAMA Cardiology AND Editorial: Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality (03/2020)
- Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers – Hypertension AND Commentary: COVID-19 alert: Heart and kidney patients should keep taking their medicines – University of Miami Miller School of Medicine (03/2020)
- Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease – Circulation (03/2020)
- COVID-19 and the cardiovascular system – Nature Reviews Cardiology (03/2020)
- Cardiologists and Coronavirus: Looking after ourselves and each other so we can continue to look after patients – Heart (03/2020)
- Coronaviruses and the cardiovascular system: acute and long-term implications – European Heart Journal (03/2020)
- SARS-CoV-2: a potential novel etiology of fulminant myocarditis – Herz (03/2020)
COVID-19 Cardiology: This page will be updated as often as necessary and will be fixed in the right column on our homepage.
Review: Anti-arrhythmic Properties of Non-antiarrhythmic Medications
24 Mar, 2020 | 11:12h | UTCAnti-arrhythmic properties of non-antiarrhythmic medications – Pharmacological Research (free)
Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic
20 Mar, 2020 | 11:05h | UTCCommentary: CVD in the Setting of COVID-19: Considerations to Prepare Patients, Providers, Health Systems – American College of Cardiology (free)
FDA: Stop SGLT2 Inhibitors Before Scheduled Surgery
20 Mar, 2020 | 10:52h | UTCCommentary: FDA advises stopping SGLT2 inhibitor treatment prior to surgery – The Hospitalist (free)
“- Canagliflozin, dapagliflozin, and empagliflozin should each be discontinued at least three days before scheduled surgery.
– Ertugliflozin should be discontinued at least four days before scheduled surgery.
– Blood glucose levels should be carefully monitored after discontinuation of the SGLT2 inhibitor and appropriately managed before surgery.”
Cohort Study: Associations of Fat and Carbohydrate Intake with Cardiovascular Disease and Mortality
20 Mar, 2020 | 10:48h | UTC
ACC: Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic
19 Mar, 2020 | 10:46h | UTCCommentary: COVID-19 Poised to Upend the Cath Lab, ACC and SCAI Say – TCTMD (free)
Coronaviruses and the Cardiovascular System: Acute and Long-term Implications
19 Mar, 2020 | 10:43h | UTC
Study: Using Artificial Intelligence to Analyze CT Scans may Better Predict Cardiovascular Risk than Established Clinical Parameters
18 Mar, 2020 | 09:45h | UTCCommentaries: Artificial intelligence-derived imaging biomarkers to improve population health – The Lancet Digital Health (free) AND Artificial Intelligence Predicts Heart Disease Risk from CT Scans – NIH Research Matters (free)